x
Loading
+ -

Balzan Prize for Michael N. Hall from the University of Basel

Prof. Dr. Michael N. Hall. (Image: University of Basel, Biozentrum, Matthew Lee)
Prof. Dr. Michael N. Hall. (Image: University of Basel, Biozentrum, Matthew Lee)

Prof. Dr. Michael N. Hall from the Biozentrum of the University of Basel has been awarded the 2024 Balzan Prize for Biological Mechanisms of Ageing. The cell biologist discovered the protein TOR (target of rapamycin), a key regulator of cell growth and metabolism, which has also been implicated in development, ageing and a wide variety of diseases such as cancer and diabetes.

09 September 2024

Prof. Dr. Michael N. Hall. (Image: University of Basel, Biozentrum, Matthew Lee)
Prof. Dr. Michael N. Hall. (Image: University of Basel, Biozentrum, Matthew Lee)

Michael N. Hall receives the Balzan Prize for his groundbreaking contributions to our understanding of the molecular mechanisms that regulate cell growth and ageing. Michael Hall discovered two proteins, TOR1 and TOR2, which regulate cell growth and metabolism in response to nutrients. These play a central role in the ageing process and in the development of age-related diseases such as cancer, diabetes and cardiovascular diseases.

The other winners of the 2024 Balzan Prize are the criminologist John Braithwaite from the Australian National University, the historian of science Lorraine Daston, Director at the Max Planck Institute for the History of Science, and the American chemist Omar Yaghi from the University of California Berkeley.

The four prize winners were announced today by the International Balzan Foundation in Milan. This year's Balzan Prizes are awarded for research areas ranging from law to the history of science and from the biology of ageing to innovative materials. The prizes are endowed with 750,000 Swiss francs each, and it is expected that the prize winners will use half of the prize money to fund research projects involving a new generation of young researchers. The award ceremony will take place on November 21 in Rome in the presence of the President of the Italian Republic.

Multi-award winning researcher

For more than thirty years, Prof. Michael N. Hall has been working at the University of Basel’s Biozentrum. Here he discovered the protein kinase “Target of Rapamycin”, TOR for short, in the early 1990s. This protein controls cell growth and size by activation or inactivation of different signaling pathways. Dysregulation of the large TOR signaling network is involved in ageing processes and diseases such as cancer and diabetes.

To top